Range tightening and setting lower highThis nasdaq daily top gainer had a run from this morning to the upside. this move is fading and reaching a tightening range or equillibrium and setting a lower high around the .5 fib retracement level and vwap. td9 has printed bull exhastion and ttm has signaled contraction.
GlycoMimetics, Inc.
0.2482USDR
−0.0135−5.16%
At close at May 21, 23:18 GMT
USD
No trades
Next report date
≈
July 30
Report period
Q2 2025
EPS estimate
0.00 USD
Revenue estimate
0.00 USD
−0.4572 USD
−37.88 M USD
0.00 USD
56.12 M
About GlycoMimetics, Inc.
Sector
Industry
Website
Headquarters
Rockville
Founded
2003
FIGI
BBG001J1BQN9
GlycoMimetics, Inc. is a biotechnology company, which engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
−12.00 M
−9.00 M
−6.00 M
−3.00 M
0.00
Revenue
Net income
Net margin %
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
−2.40 M
−1.80 M
−1.20 M
−600.00 K
0.00
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
−2.40 M
−1.80 M
−1.20 M
−600.00 K
0.00
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
−11.00 M
0.00
11.00 M
22.00 M
33.00 M
Debt
Free cash flow
Cash & equivalents
No news here
Looks like there's nothing to report right now
GLYC - Another Nasdaq ShortHere's another Nasdaq stock to short in consideration that there may be a correction coming.
GLYC has printed the SRP shakeout up-down whipsaw that is so often a signal that the trend has changed (as we saw with Bitcoin recently).
Strong bearish RSI divergence since much lower in the uptrend could
NShort

5 Hot Biotechs to Hold Over The WeekendMy Post-FDA Over-The-Weekend Watchlist:
$GLYC
$ONCT
$ONCY
$PIRS
$AGEN
All of these biotechs have phase one cancer treatment clinical-trial data releases this weekend. Based on my research, these are the ones that I think are most likely to release good data. Since they are all in phase one, it is
NLong

$GLYC Releases Trial Data For Cancer Treatment On The 10thFundamental Analysis:
GlycoMimetics, Inc. is a clinical-stage biotechnology company that focuses on developing glycomimetics that inhibit disease-related functions of carbohydrates. They are currently developing a treatment for hormone receptor-positive metastatic breast cancer . The drug, GMI-13
NLong

GLYC BullishMACD cross and yesterday's candle closing over the 38% fib level is very bullish. Also, the proximity to the POC line (red) looks like a low-risk entry. Looking for $4.25, $4.44, and $4.72 in the short term.
NLong

NLong

GLYC - Fallen angel Long setup GLYC- Possible long here with stop at 5.24, Momentum play with first target at 7.83.
NLong

GLYC look for the 26 break here. Biotech with bullish momentum Buy the Dips here. Strong momentum and will break 26. Data release on their earnings date in early March provides a great entry opportunity. Would NOT be surprised to see this bought out either. $30 price target on a swing/ $50 by EOY
NLong

See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of GLYC is 0.2482 USD — it has decreased by −5.16% in the past 24 hours. Watch GlycoMimetics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange GlycoMimetics, Inc. stocks are traded under the ticker GLYC.
GLYC stock has fallen by −6.57% compared to the previous week, the month change is a 11.18% rise, over the last year GlycoMimetics, Inc. has showed a −13.94% decrease.
GLYC reached its all-time high on Feb 15, 2018 with the price of 26.0500 USD, and its all-time low was 0.1406 USD and was reached on Oct 9, 2024. View more price dynamics on GLYC chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
GLYC stock is 8.84% volatile and has beta coefficient of 0.95. Track GlycoMimetics, Inc. stock price on the chart and check out the list of the most volatile stocks — is GlycoMimetics, Inc. there?
Today GlycoMimetics, Inc. has the market capitalization of 16.89 M, it has increased by 4.68% over the last week.
Yes, you can track GlycoMimetics, Inc. financials in yearly and quarterly reports right on TradingView.
GlycoMimetics, Inc. is going to release the next earnings report on Jul 30, 2025. Keep track of upcoming events with our Earnings Calendar.
GLYC net income for the last quarter is −2.34 M USD, while the quarter before that showed −7.22 M USD of net income which accounts for 67.55% change. Track more GlycoMimetics, Inc. financial stats to get the full picture.
No, GLYC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 22, 2025, the company has 26 employees. See our rating of the largest employees — is GlycoMimetics, Inc. on this list?
Like other stocks, GLYC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GlycoMimetics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GlycoMimetics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GlycoMimetics, Inc. stock shows the sell signal. See more of GlycoMimetics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.